For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

Researchers have developed a gene therapy that may provide a long-term treatment for hypophosphatasia. Unlike current ...

Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection Essentials collection Artificial Intelligence Trending searches Video Woman ...

DNSFilter announced today the release of its 2025 Annual Security Report, showcasing an uptick in malicious requests from 2023 to 2024. At internet scale, threats are relentless, but so is the right ...

The firm will begin testing a second dose cohort with AMT-191 after receiving a positive recommendation from a data monitoring committee.